"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
- Clinician Information:
Magnevist Patient Information including How Should I Take
In this Article
- What is gadopentetate dimeglumine (Magnevist)?
- What are the possible side effects of gadopentetate dimeglumine (Magnevist)?
- What is the most important information I should know about gadopentetate dimeglumine (Magnevist)?
- What should I discuss with my health care provider before receiving gadopentetate dimeglumine (Magnevist)?
- How is gadopentetate dimeglumine used (Magnevist)?
- What happens if I miss a dose (Magnevist)?
- What happens if I overdose (Magnevist)?
- What should I avoid after receiving gadopentetate dimeglumine (Magnevist)?
- What other drugs will affect gadopentetate dimeglumine (Magnevist)?
- Where can I get more information?
What should I discuss with my health care provider before receiving gadopentetate dimeglumine (Magnevist)?
Gadopentetate dimeglumine can cause a life-threatening condition in people with advanced kidney disease. The symptoms of this condition include:
- burning, itching, swelling, scaling, and tightening or hardening of your skin;
- muscle weakness;
- joint stiffness in your arms, hands, legs, or feet;
- deep bone pain in your ribs or your hips;
- trouble moving; or
- skin redness or discoloration.
Before receiving this medication, tell your doctor if you have kidney disease or if you are on dialysis. You may not be able to receive gadopentetate dimeglumine.
To make sure you can safely receive this medication, tell your doctor if you have any of these other conditions:
- high blood pressure;
- liver disease (or liver transplant);
- asthma, hay fever, or a history of food or drug allergies;
- if you are over 60 years old;
- if you have ever had any type of reaction to a contrast agent; or
- if you have recently had an injury, surgery, or severe infection.
FDA pregnancy category C. It is not known whether gadopentetate dimeglumine will harm an unborn baby. Before you receive this medication, tell your doctor if you are pregnant.
Gadopentetate dimeglumine can pass into breast milk and may harm a nursing baby. Do not receive this medication without telling your doctor if you are breast-feeding a baby.
How is gadopentetate dimeglumine used (Magnevist)?
Gadopentetate dimeglumine is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting during your MRI.
Your doctor or other healthcare provider may want to watch you for a short time after your test is over. This is to make sure you do not have any unwanted side effects or delayed reactions.
Additional Magnevist Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.